KZIA ▲ +0.6% - Kazia Therapeutics Limited $KZIA KZIA - Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders Kazia Therapeutics rose 0.6% after announcing that its partner Sovargen Company has dosed the first patient in a Phase 1b/2a clinical trial of paxalisib for rare seizure disorders. The milestone represents progress toward potential new therapeutic applications for the company's investigational drug candidate. 22-SEP-2026 07:30 AM ET